Arca
Skip to content

COPAL® exchange G hip spacer and 1 more

Prosthesis, Hip, Hemi-, Femoral, Metal. 510(k) K234028, from Heraeus Medical GmbH (Wehrheim, DE). Product code KWL, class 2.

As of Nov 17, 2026, K234028 is an FDA 510(k) held by Heraeus Medical GmbH, substantially equivalent on Feb 15, 2024 after 57 days, with no recalls tied to it in FDA's recall database.

  • Substantially equivalent: Feb 15, 2024
  • Review time: 57 days
  • Recalls: 0

Indications for Use

As the 510(k) summary states them, read from FDA's summary PDF

COPAL® exchange G hip spacer; COPAL® exchange G hip spacer (polymethylmethacrylate / gentamicin) is indicated for temporary use (maximum of 180 days) as a total hip replacement (THR) in skeletally mature patients undergoing a two-stage procedure due to a septic process.

Predicate Devices

The legally marketed devices this 510(k) summary says it is substantially equivalent to, read from FDA's summary PDF

Other KWL Clearances

The newest 510(k)s for the same product code; their median review was 51 days; see every KWL device

Record

Type
Traditional
Received
Dec 20, 2023
Review panel
Orthopedic
Regulation
21 CFR 888.3360

One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.